Robert V. Rawson

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 06, 2026

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Journal: JCO precision oncology

Published: March 12, 2026

Neutrophilic Accruing Hidradenitis in a Patient With Intranasal Cocaine Use.

Neutrophilic Accruing Hidradenitis in a Patient With Intranasal Cocaine Use.

Journal: The Australasian journal of dermatology

Published: November 28, 2025

Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 23, 2025

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Journal: Nature medicine

Published: July 10, 2025

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

Journal: Journal for immunotherapy of cancer

Published: March 10, 2025

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 05, 2025

Cartilage Resection in the Surgical Management of Ear Melanoma.

Cartilage Resection in the Surgical Management of Ear Melanoma.

Journal: Annals of surgical oncology

Published: January 06, 2025

Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort.

Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: December 12, 2024

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

Journal: Nature medicine

Published: July 24, 2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Journal: The New England journal of medicine

Published: June 03, 2024

The Prognostic Significance of Tumoral Melanosis.

The Prognostic Significance of Tumoral Melanosis.

Journal: Journal of cutaneous pathology

Published: May 02, 2024

Showing 1-12 of 65

Last Updated: 09/26/2026